NZ792694A - Novel glutaminyl cyclase inhibitors - Google Patents

Novel glutaminyl cyclase inhibitors

Info

Publication number
NZ792694A
NZ792694A NZ792694A NZ79269418A NZ792694A NZ 792694 A NZ792694 A NZ 792694A NZ 792694 A NZ792694 A NZ 792694A NZ 79269418 A NZ79269418 A NZ 79269418A NZ 792694 A NZ792694 A NZ 792694A
Authority
NZ
New Zealand
Prior art keywords
amino
heteroaryl
heterocyclyl
cycloalkyl
aryl
Prior art date
Application number
NZ792694A
Other languages
English (en)
Inventor
Antje Meyer
Ulrich Heiser
Torsten Hoffmann
Ingeborg Lues
Original Assignee
Vivoryon Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivoryon Therapeutics N V filed Critical Vivoryon Therapeutics N V
Publication of NZ792694A publication Critical patent/NZ792694A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ792694A 2017-03-31 2018-04-03 Novel glutaminyl cyclase inhibitors NZ792694A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1705263.0A GB201705263D0 (en) 2017-03-31 2017-03-31 Novel inhibitors
NZ757601A NZ757601A (en) 2017-03-31 2018-04-03 Novel glutaminyl cyclase inhibitors

Publications (1)

Publication Number Publication Date
NZ792694A true NZ792694A (en) 2025-10-31

Family

ID=58682483

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ792694A NZ792694A (en) 2017-03-31 2018-04-03 Novel glutaminyl cyclase inhibitors
NZ757601A NZ757601A (en) 2017-03-31 2018-04-03 Novel glutaminyl cyclase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ757601A NZ757601A (en) 2017-03-31 2018-04-03 Novel glutaminyl cyclase inhibitors

Country Status (15)

Country Link
US (2) US11339152B2 (enExample)
EP (1) EP3601269A1 (enExample)
JP (3) JP7674811B2 (enExample)
KR (2) KR20250002689A (enExample)
CN (2) CN110719910B (enExample)
AU (2) AU2018246382C1 (enExample)
BR (1) BR112019019553A2 (enExample)
CA (2) CA3057783A1 (enExample)
EA (1) EA201992120A1 (enExample)
GB (1) GB201705263D0 (enExample)
IL (3) IL297534A (enExample)
MX (2) MX2019011544A (enExample)
NZ (2) NZ792694A (enExample)
WO (1) WO2018178384A1 (enExample)
ZA (1) ZA201905811B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM
EP3861001B1 (en) * 2018-10-05 2023-12-13 Pfizer Inc. Boron containing pde4 inhibitors
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
CN113365978A (zh) * 2019-01-06 2021-09-07 普梭梅根公司 Htra抑制剂和caga抑制剂及其应用
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
EP4065553B1 (en) * 2020-01-17 2025-01-29 Daegu-Gyeongbuk Medical Innovation Foundation Novel compound, preparation method thereof, and use thereof
KR102433502B1 (ko) * 2020-01-17 2022-08-18 재단법인 대구경북첨단의료산업진흥재단 신규 화합물, 이의 제조방법 및 이의 용도
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US20230382891A1 (en) * 2020-10-20 2023-11-30 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
LT4259617T (lt) * 2020-12-10 2024-12-10 Bayer Aktiengesellschaft Pakeistos pirazolo piperidino karboksirūgštys
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
EP4387552A4 (en) 2021-08-18 2025-04-30 Augmedics Ltd. AUGMENTED REALITY SURGICAL SYSTEM USING DEPTH SENSING
CN117567435A (zh) * 2022-01-30 2024-02-20 上海市第十人民医院 谷氨酰胺环化酶抑制剂及其应用
WO2023205173A1 (en) * 2022-04-20 2023-10-26 Blacksmith Medicines, Inc. Substituted piperidines and substituted tetrahydropyridines as immune-modulating compounds
WO2023203521A1 (en) 2022-04-21 2023-10-26 Augmedics Ltd. Systems and methods for medical image visualization
CN114560817B (zh) * 2022-04-25 2022-10-25 北京大学第三医院（北京大学第三临床医学院） 一种用于抑制纤维化的小分子药物及其应用
AR130003A1 (es) 2022-08-03 2024-10-23 Boehringer Ingelheim Int Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-péptido ciclotransferasa y proteína tipo glutaminil-péptido ciclotransferasa
IL319523A (en) 2022-09-13 2025-05-01 Augmedics Ltd Augmented reality glasses for image-guided medical intervention
WO2024131742A1 (zh) * 2022-12-20 2024-06-27 深圳湾实验室 一种靶向usp1的小分子抑制剂及其应用
AU2023411110A1 (en) 2022-12-22 2025-04-24 Boehringer Ingelheim International Gmbh Phenylpiperidine derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
AU2024236795A1 (en) 2023-03-13 2025-06-26 Boehringer Ingelheim International Gmbh Phenylpiperidine derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
US20250059165A1 (en) 2023-08-04 2025-02-20 Boehringer Ingelheim International Gmbh Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
TW202521532A (zh) 2023-08-04 2025-06-01 德商百靈佳殷格翰國際股份有限公司 作為麩醯胺醯基肽環轉移酶及麩醯胺醯基肽環轉移酶樣蛋白之抑制劑的哌啶基吡啶基甲腈衍生物
US20250066329A1 (en) 2023-08-14 2025-02-27 Boehringer Ingelheim International Gmbh Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
CN117538462B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种氨氯地平贝那普利胶囊有关物质的检测方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2114662T3 (es) * 1993-08-26 1998-06-01 Ono Pharmaceutical Co Derivados de la 4-aminopirimidina.
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
WO2003004488A1 (en) * 2001-07-03 2003-01-16 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US20090048301A1 (en) * 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
EA011300B1 (ru) * 2003-07-16 2009-02-27 Янссен Фармацевтика Н.В. Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
ES2287896T3 (es) * 2004-01-12 2007-12-16 Laboratoires Serono Sa Derivados de tiazol y uso de los mismos.
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
BRPI0513405A (pt) * 2004-07-16 2008-05-06 Sunesis Pharmaceuticals Inc tienopirimidinas úteis como inibidores de aurora quinase
MX2007001399A (es) * 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
JP2009531274A (ja) * 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド キナーゼ阻害性ピロロピリジン化合物
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
AU2007272972B2 (en) * 2006-07-14 2011-12-01 Chemocentryx, Inc. Triazolyl pyridyl benzenesulfonamides as CCR2 or CCR9 modulators for the treatment of atherosclerosis
CA2673003A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
BRPI0720635A2 (pt) * 2006-12-22 2014-01-07 Novartis Ag Compostos orgânicos e seus usos
EP2200436B1 (en) * 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
AU2009282567B2 (en) * 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5707327B2 (ja) * 2008-09-04 2015-04-30 プロビオドルグ エージー 新規の阻害剤
EP2475428B1 (en) * 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
BR112012022478B1 (pt) * 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
JP5945532B2 (ja) * 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2638018A1 (en) * 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
ES2746134T3 (es) * 2010-11-10 2020-03-04 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de LRRK2
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
BR112014026952B1 (pt) * 2012-05-03 2022-03-15 Genentech, Inc Derivados de aminopirimidina pirazol e composição que os compreende
WO2014081718A1 (en) * 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
JP6454651B2 (ja) * 2013-03-15 2019-01-23 プロビオドルグ エージー 新規阻害剤
MA40957A (fr) * 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
CA2979302A1 (en) * 2015-05-13 2016-11-17 Selvita S.A. Substituted quinoxaline derivatives
US10544095B2 (en) * 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US10221191B2 (en) * 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

Also Published As

Publication number Publication date
ZA201905811B (en) 2020-06-24
JP7674811B2 (ja) 2025-05-12
US20220274977A1 (en) 2022-09-01
JP2024153639A (ja) 2024-10-29
KR102737532B1 (ko) 2024-12-04
IL269196B2 (en) 2024-04-01
BR112019019553A2 (pt) 2020-04-22
WO2018178384A1 (en) 2018-10-04
CN110719910A (zh) 2020-01-21
JP7589191B2 (ja) 2024-11-25
AU2018246382B2 (en) 2022-06-16
GB201705263D0 (en) 2017-05-17
IL269196B1 (en) 2023-12-01
JP2022110130A (ja) 2022-07-28
EP3601269A1 (en) 2020-02-05
MX2019011544A (es) 2019-12-16
CA3221839A1 (en) 2018-10-04
AU2018246382C1 (en) 2024-07-04
US12384772B2 (en) 2025-08-12
AU2022246405A1 (en) 2022-10-27
IL269196A (en) 2019-11-28
CA3057783A1 (en) 2018-10-04
US11339152B2 (en) 2022-05-24
NZ757601A (en) 2023-02-24
AU2022246405B2 (en) 2024-08-01
JP2020512373A (ja) 2020-04-23
IL297534A (en) 2022-12-01
KR20250002689A (ko) 2025-01-07
KR20190136005A (ko) 2019-12-09
US20200377493A1 (en) 2020-12-03
MX2022007317A (es) 2022-07-13
CN110719910B (zh) 2023-07-21
CN117024352A (zh) 2023-11-10
AU2018246382A1 (en) 2019-10-17
EA201992120A1 (ru) 2020-01-29
IL307911A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
NZ792694A (en) Novel glutaminyl cyclase inhibitors
NZ712352A (en) Novel inhibitors of glutaminyl cyclase
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
MX380929B (es) Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
WO2015200677A3 (en) Prmt5 inhibitors and uses thereof
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
PH12021550400A1 (en) Cardiac sarcomere inhibitors
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MX383363B (es) Compuestos macrociclicos como inhibidores de cinasas asociadas al receptor de interleucina1/4 (irak1/4) y usos de los mismos.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
TN2011000400A1 (en) Inhibitors of beta-secretase
EA202091893A1 (ru) Новые кристаллические формы
BRPI0618885A8 (pt) compostos heterocíclicos tendo atividade inibitória de 11beta-hidroxiesteroide deidrogenase tipo i
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
PH12012500770A1 (en) 5-hydroxypyrimidine-4-carboxamide derivative
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
MX2021011376A (es) Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.
PH12018502012A1 (en) Griseofulvin compound
MX2009004290A (es) Inhibidores de proteasas de catepsina.
WO2019023216A8 (en) INHIBITORS OF ROR GAMMA
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2021002524A (es) Nuevas formas de sal de clorhidrato de un inhibidor de cinasa estructurada por sulfonamida.
EA202090642A1 (ru) Ингибиторы глутаминилциклазы
EP4458846A3 (en) Novel compounds and their use as selective inhibitors of caspase-2